Key Drivers
- Strong cash flow
- Low capital efficiency
- Intangible-heavy assets
AIAI Summary
Revvity is still a quality cash-generating business, but the key takeaway is that China immunodiagnostics weakness and below-consensus guidance have turned it from a “steady compounder” into a premium-valued name that needs clear near-term stabilization before upside is credible.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •Low capital efficiency
- •Intangible-heavy assets
RVTY generates strong and consistent cash flow with acceptable leverage and liquidity, but its low capital efficiency, intangible-heavy balance sheet, and rich valuation suggest limited upside unless margins stay resilient.
Price Behavior
Key Price Behavior Insights:
- •Selloff defended
- •Resistance capped
- •Momentum faded
Over the last month, RVTY recovered from a sharp selloff but remains capped by $99-$101 resistance, with support at $93-$94 and fading near-term momentum.
Sharp drop to $82.26, then rebound to $101.00 before fading back
Sentiment & News
Key News Insights:
- •Q1 Beat
- •China Headwinds
- •FDA Clearance
Revvity posted a solid Q1 earnings beat on strong diagnostics execution and 3% organic growth, while margin pressure and China headwinds remain the main near-term offsets as product expansion continues.
The results and new assay clearance are positive for momentum, but regional and margin pressures could cap near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings